Ricardo plc Completes Acquisition of E3-Modelling to Expand Its Environmental Modelling Tools
25.1.2023 12:00:00 EET | Business Wire | Press release
Ricardo plc, a global strategic, environmental and engineering consulting company, today announces the acquisition of a 93% shareholding of E3-Modelling S.A., a consultancy specialising in delivering advanced empirical modelling of the energy-economy-environment nexus.
E3M’s 34-strong team develops and maintains large-scale models across the energy, environment and transport sectors. Its expertise focuses on the design and impact analysis of the transition of all possible types of power generation technologies, several types of alternative green fuels, energy demand efficiency and mobility restructuring, taking into account the impact of major energy policies on the economies of European countries and globally, with details for more than 50 economic activities. Its integrated modelling tools provide informed, transparent and robust analysis as well as recommendations for its high-profile clients which include the European Commission, national governments, energy regulators and a number of private companies in the energy and transport sectors, financial institutions and strategic consultancies.
Over the past 30 years, E3-Modelling has carried out consultancy on all major European energy and climate policy initiatives, and its large-scale energy, economy and transport models have been applied at the very heart of European Commission policymaking.
“Ricardo’s acquisition of E3-Modelling is fully aligned with our ambition to become a global leader in strategy and engineering consultancy for environmental and energy-transition solutions.” said, Graham Ritchie, Ricardo CEO. “It provides an opportunity to deliver repeatable digital models focused on energy markets, climate change and the decarbonisation of transport to governments and corporate clients globally. We already have a strong working relationship with E3-Modelling having worked together for over 10 years, and this acquisition is a natural advancement, combining our skillsets to offer a transformational contribution to Ricardo’s energy and environmental services portfolio.”
Prof. Emeritus Pantelis Capros and Dr. Leonidas Paroussos of E3-Modelling S.A. added: "We are very excited to be joining an energy & environmental consultancy of Ricardo’s pedigree and to see the business we've built embark on its next stage of growth. By leveraging Ricardo’s scale and resources, we will be able to expand our reach beyond Europe and broaden our modelling services as we assess the implications of energy, climate and sustainable development policies for our clients.”
E3M provides digital modelling capabilities right across the markets that Ricardo serves, making the acquisition highly complementary to Ricardo’s unique position at the intersection of the energy, environment and mobility agendas. To date, the use of E3M’s models has largely focused on Europe and neighbouring countries. The combination of E3M’s capabilities and expertise with Ricardo’s global footprint, services and diversified market expansion will support the Group in creating additional value for its global client base that are focused on their transition towards a low-carbon future.
~ENDS~
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and close to 3,000 colleagues in more than 20 countries, we provide exceptional levels of expertise in delivering innovative cross-sector sustainable outcomes to support energy transition and scarce resources, environmental services together with safe and smart mobility. Our global team of consultants, environmental specialists, engineers and scientists support our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
About E3-Modelling
E3-Modelling is a société anonyme (S.A.) company, established in Greece, as a knowledge-intensive consulting company. We deliver consulting services based on the large-scale empirical modelling of the economy-energy-environment nexus: PRIMES, GEM-E3 and Prometheus. We focus on the design of transition in the energy market and systems, both demand and supply of energy, towards green and climate-friendly structures and technologies. With the modelling, we help to assess the transitions from economic, policy and implementation perspectives putting emphasis on the functioning of the system and the markets as a whole when policy instruments influence behaviours and market outcomes. Visit www.e3modelling.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005530/en/
Contact information
Media contacts:
Natasha Perfect, Ricardo Natasha.perfect@ricardo.com
Elisabeth Cowell, SECNewgate ricardo@secnewgate.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom